Cary G. Vance
President and Chief Executive Officer
Mr. Vance was appointed President and CEO of Titan Medical in July 2022. Prior to being appointed, he served as an independent director for Titan Medical’s Board of Directors and as the company’s Human Resources/Compensation Committee Chair leading the company’s compensation policies and philosophical direction.
Previously, he served as President and CEO at Xcath Incorporated and drove strategic and tactical initiatives to advance the robotic platform enabling precise manipulation of robotically steerable guidewires for neurovascular and peripheral vascular clinical applications. Prior to Xcath, Mr. Vance led OptiScan Biomedical Corporation as President and CEO, leveraging a novel medical technology platform that continuously monitored systems in the surgical intensive care unit.
Prior to this, Mr. Vance served as President and CEO at Myoscience Incorporated, and President and CEO of Hansen Medical Inc. While at
Hansen Medical, he strategically transformed the business and markets with disruptive, enabling and game-changing interventional robotic techniques and technology. Mr. Vance drove adoption and record levels of year-over-year catheter utilization and system placements, while significantly reducing and reallocating spending levels. He later executed on an equity and debt financing strategy as an integral step to a successful M&A event. Prior to Hansen, Mr. Vance served in various global executive leadership roles over 20 years at Teleflex, Covidien and GE Healthcare. Mr. Vance currently serves on the AdvaMed Accel Board of Directors and is NACD Directorship Certified and is Lean/Six Sigma Black Belt Certified. Mr. Vance earned both a Bachelor of Arts degree in Economics and an MBA from Marquette University.
Chief Financial Officer
Mr. Lemieux has more than 18 years of experience in public companies including over 9 years as a Chief Financial Officer and 13 years in the health care industry. Mr. Lemieux has been involved with or led numerous debt and equity financings, licensing and M&A transactions valued at over $400 million. Mr. Lemieux served as CFO and Secretary of NeuPath Health (TSXV: NPTH) from 2019 to 2021.
Prior to NeuPath, Mr. Lemieux served as the CFO and Secretary at Cipher Pharmaceuticals (TSX:CPH) from 2016 to 2019 and acted as Interim-CEO from November 2016 to April 2017. Prior to Cipher Pharmaceuticals, Mr. Lemieux was CFO at Nuvo Pharmaceuticals (TSX:NRI) and Crescita Therapeutics (TSX:CTX). Crescita was created on March 1, 2016 by way of a plan of arrangement that reorganized Nuvo Research Inc. into Nuvo and Crescita. Mr. Lemieux is a Chartered Professional Accountant and holds a Master of Management & Professional Accounting degree from the University of Toronto.
Vice President, Legal, IP and Strategic Initiatives, General Counsel
Mr. Brar draws from more than 15 years of technical, business and legal experience to manage Titan’s legal affairs while leading and executing a comprehensive IP program that facilitates innovation, enhances business objectives and mitigates risks. Working alongside other Titan executives, engineering teams and advisers, Mr. Brar ensures that the company’s IP strategy remains in alignment with – and continues to influence and enhance – the company’s overall business strategy.
Before joining Titan, Mr. Brar practiced with the law firm of Smart & Biggar in Vancouver, British Columbia. Before practicing law, he worked as an engineer and in product marketing with National Semiconductor in Santa Clara, California. Mr. Brar is deeply passionate about innovation that enhances people’s quality of life and the role of intellectual property in driving, supporting and testing such innovation. He has a Law degree (LL.B.) and a Bachelor of Science degree in Computer Engineering, both from the University of Manitoba.
Vice President, Quality and Regulatory Affairs
Ms. Carrea has more than 25 years of experience in managing quality assurance and regulatory affairs activities in the medical device industry, including robotic assisted surgery. Ms. Carrea has been responsible for global submissions and registrations for Class 1, 2, and 3 medical devices including De Novo applications.
Ms. Carrea served as Vice President, Regulatory and Clinical Affairs and Security Officer of Translational Imaging Innovations, Inc, from 2019 to 2021. Prior to this, she served as Vice President, Quality and Regulatory at Baebies, Inc, from 2016 to 2019. In 2015, she served as Director, Quality and Regulatory Affairs for Bioptigen. From 2009-2014, Ms. Carrea was Vice President Quality Assurance and Regulatory Affairs at TransEnterix Inc, (now Asensus Surgical Inc, NYSE American: ASXC). Ms. Carrea holds a Bachelor of Science Degree in Materials Science and Engineering from North Carolina State University, and a Master of Science Degree in Quality and Regulatory Affairs from Temple University, with a concentration in medical devices and clinical research.
Vice President, Manufacturing and Operations
Mr. Fahey brings more than 20 years of product development, manufacturing and commercialization experience in the medical device industry. He has been responsible for creating and leading product development engineering teams and processes to meet regulatory requirements, execute on strategy and foster cross-functional efficiency and accountability.
Most recently, Mr. Fahey served as Senior Vice President of Engineering at Precision Spine/Spinal USA, a spinal implant company where he drove multiple product releases and line extensions that were manufactured in-house. Before joining Precision Spine, Bill spent over five years with Orthofix/Blackstone Medical Inc. as Sr. Director of Engineering. He also held a product development position in Stryker’s Spine division. Mr. Fahey holds a Bachelor of Science Degree in Mechanical Engineering from Villanova University.
Vice President, Investor Relations & Corporate Communications
Ms. Galfetti has over 20 years of experience leading investor relations and corporate communications programs. Most recently, Ms. Galfetti provided consulting services to small and medium companies in the life science industries.
Her corporate experience includes serving as Vice President, Investor Relations & Corporate Communications at Cynapsus Therapeutics. Prior to Cynapsus, she was Senior Director, Investor Relations at Sanofi, responsible for integrating the Genzyme Corporation investor relations program post-merger. Prior to Sanofi, Ms. Galfetti was Senior Director, Corporate Communications and Investor Relations at AMAG Pharmaceuticals. Prior to AMAG, Ms. Galfetti held Investor Relations roles of increasing responsibility at Genzyme Corporation. Ms. Galfetti holds a Bachelor of Arts in Political Science from the University of Vermont and a Master of Business Administration (with distinction) from Bentley University.
Vice President, Market and Corporate Development
Mr. Heinz has more than 20 years of medical device experience across business strategy, corporate development, product development and marketing for companies ranging in size from small-cap to multi-nationals. He recently served as Director, Business Development (M&A) for Smith & Nephew, where he led teams responsible for executing upon the inorganic growth strategy via M&A, equity investments and co-development partnerships.
Prior to joining Smith & Nephew, Mr. Heinz consulted to ZimmerBiomet, Medtech Surgical SA and a boutique investment bank, managing quality remediation, market development and private placement projects, respectively. He also served as senior marketing manager for the SYMBIS Surgical System MRI-compatible neurosurgical robotics business at IMRIS, and as a product manager over the $500m instruments, accessories and video system portfolio at Intuitive Surgical. Mr. Heinz holds a Master of Engineering Management from Christian Brothers University, a Bachelor of Science in Bioengineering from The University of Illinois, Urbana-Champaign, and is anticipated to graduate with an Executive MBA degree from the Kellogg School of Management at Northwestern University in December 2022.
Vice President, Finance
Mr. Huang is a financial executive with over 20 years of experience developing and implementing financial models and systems, and accounting practices to support the achievement of strategic corporate objectives.
Mr. Huang has strong expertise in evaluating investment opportunities and long-term value creation as well as extensive knowledge of IFRS and U.S. GAAP reporting requirements. Most recently, he served as Senior Vice President, Corporate Finance at Quarterhill Inc., where he led the finance systems migration and reorganized key business processes, streamlining external reporting processes. Prior to Quarterhill, Mr. Huang served as Vice President, Finance at Aralez Pharmaceuticals, responsible for implementing systems upgrades, negotiating potential divestitures and advising on private equity financing. Prior to this, Mr. Huang was Senior Director, Finance at Astellas Pharma. Mr. Huang holds a Bachelor of Science in Physiology from the University of Toronto, a Graduate Diploma in Public Accountancy from McGill University, and has Chartered Accountant Designation.
Director of Human Resources
Mr. Jones has more than 30 years of experience in Human Resources, including 10 years with medical device companies. He has led efforts to support business growth through development culture shifts, mergers and acquisitions, and rapid scaling of integrated businesses both domestically and internationally.
Mr. Jones’ experience also includes leadership and employee development, compensation, talent acquisition, sales force effectiveness and manufacturing. Mr. Jones served as Director of Human Resources for Teleflex Medical’s Anesthesia and Emergency Medicine Business Unit from 2013 to 2022. Prior to this, he served as Vice President, Human Resources with inVentiv Health. He held Human Resources Director roles at Bayer CropScience and Pepsi Cola Company. Prior to these roles, he held several HR roles with Johnson & Jonson, concluding there as an Organizational Effectiveness Manager. Mr. Jones graduated from West Virginia University with a Master of Industrial and Labor Relations and a Bachelor of Public Relations and holds a Senior Professional in Human Resources (SPHR) Certification.
Vice President, Upstream Marketing
Mr. Seibert has 16+ years of experience in the medical device industry, spanning clinical sales, sales leadership, strategic planning and product development at companies ranging from those with a very mature product lifecycle to early stage, pre-submission products.
Mr. Seibert has spent 15 years focusing on robotic medical devices, including stints of increasing levels of responsibility at both Intuitive Surgical, Inc., and Stereotaxis, Inc. Mr. Seibert has an in-depth, national network of innovative physicians and healthcare executives. He has worked for four start-up companies and has extensive relationships across the IDN/GPO landscape. Mr. Seibert has a Bachelor of Arts from the University of Alabama, a Master of Arts in Human Relations from the University of Oklahoma and an MBA from the University of South Alabama.